

(±)-5-(2-formyl-3-hydroxyphenoxy)-2-methylpentanoic acid;  
 5-(2-formyl-3-hydroxyphenoxy)-2,2-dimethylpentanoic acid;  
 methyl 3-(2-formyl-3-hydroxyphenoxy)methylbenzoate;  
 3-(2-formyl-3-hydroxyphenoxy)methylbenzoic acid;  
 benzyl 5-(2-formyl-3-hydroxyphenoxy)pentanoate;  
 5-[4-(2-formyl-3-hydroxyphenoxy)-*N*-butyl]tetrazole;  
 7-(2-formyl-3-hydroxyphenoxy)heptanoic acid;  
 5-(2-formyl-3-hydroxy-4-*n*-propoxyphenoxy)pentanoic acid;  
 5-(4,6-dichloro-2-formyl-3-hydroxyphenoxy)pentanoic acid;  
 5-(2-formyl-3-hydroxyphenoxy)-*N*-methylsulphonylpentanamide;  
 ethyl 4-(2-formyl-3-hydroxyphenoxy)methylbenzoate;  
 5-(4-chloro-2-formyl-3-hydroxyphenoxy)pentanoic acid;  
 5-(3-acetylamino-2-formyl phenoxy)pentanoic acid;  
 Aminoguanidine;  
 4-(2-formyl-3-hydroxyphenoxy)butanoic acid;  
 6-(2-formyl-3-hydroxyphenoxy)hexanoic acid;  
 ethyl 4-(3-acetylamino-2-formylphenoxy)methylbenzoate;  
 4-(3-acetylamino-2-formylphenoxy)methylbenzoic acid;  
 2-(2-formyl-3-hydroxyphenoxy)methylbenzoic acid;  
 5-[4-(2-formyl-3-hydroxyphenoxy)methyl]phenyl]tetrazole;  
 5-(2-formyl-3-hydroxy-4-methoxyphenoxy)pentanoic acid;  
 3-(2-formyl-3-hydroxyphenoxy)propionitrile;  
 4-Hydroxyphenylacetaldehyde;  
 Phenylacetaldehyde;  
 4-Methoxyphenylacetaldehyde;  
 1-hydroxy-2-phenylpropane;  
 3-Phenylpropanaldehyde;  
 4-Nitrobenzaldehyde;  
 Methyl 4-formylbenzoate;  
 4-Chlorobenzaldehyde;  
 4-Methoxybenzaldehyde;

CI  
cont

C1  
cont

4-Methylbenzaldehyde;  
8,10-Dioxoundecanoic acid;  
4,6-Dioxoheptanoic acid;  
Pentanedione;  
5-methoxy-1-tetralone;  
6-methoxy-1-tetralone;  
7-methoxy-1-tetralone;  
2-tetralone;  
3-hydroxy-1-(4-methoxyphenyl)-3-methyl-2-butanone;  
2',4'-dihydroxy-2-(4-methoxyphenyl)acetophenone;  
2-hydroxy-1-(4-methoxyphenyl)-pent-2-ene-4-one;  
Naringenin 4',5,6-trihydroxyflavonone;  
4'-methoxy-2-(4-methoxyphenyl)acetophenone;  
6,7-dihydroxycoumarin;  
7-methoxy-2-tetralone;  
6,7-dimethoxy-2-tetralone;  
6-hydroxy-4-methylcoumarin;  
Homogentisic acid gamma lactone;  
6-hydroxy-1,2-naphthoquinone;  
8-methoxy-2-tetralone;

and physiologically acceptable salts thereof, where appropriate.

C2

18. (Amended) A method of making the combination of components according to claim 24, which comprises combining a nucleotide sequence which encodes for an antigenic peptide associated with a disease state and a Schiff base forming compound which will enhance both humoral and cellular immune responses initiated by the antigenic peptide, wherein said compound is selected from the group consisting of:

4-(2-formyl-3-hydroxyphenoxy)methyl)benzoic acid;  
5-(2-formyl-3-hydroxyphenoxy)pentanamide;  
N,N-diethyl 5-(2-formyl-3-hydroxyphenoxy)pentanamide;  
N-isopropyl 5-(2-formyl-3-hydroxyphenoxy)pentanamide;

ethyl 5-(2-formyl-3-hydroxyphenoxy)pentanoate;  
 5-(2-formyl-3-hydroxyphenoxy)pentanonitrile;  
 (±)-5-(2-formyl-3-hydroxyphenoxy)-2-methylpentanoic acid;  
 5-(2-formyl-3-hydroxyphenoxy)-2,2-dimethylpentanoic acid;  
 methyl 3-(2-formyl-3-hydroxyphenoxy)methylbenzoate;  
 3-(2-formyl-3-hydroxyphenoxy)methylbenzoic acid;  
 benzyl 5-(2-formyl-3-hydroxyphenoxy)pentanoate;  
 5-[4-(2-formyl-3-hydroxyphenoxy)-*N*-butyl]tetrazole;  
 7-(2-formyl-3-hydroxyphenoxy)heptanoic acid;  
 5-(2-formyl-3-hydroxy-4-*n*-propoxyphenoxy)pentanoic acid;  
 5-(4,6-dichloro-2-formyl-3-hydroxyphenoxy)pentanoic acid;  
 5-(2-formyl-3-hydroxyphenoxy)-*N*-methylsulphonylpentanamide;  
 ethyl 4-(2-formyl-3-hydroxyphenoxy)methylbenzoate;  
 5-(4-chloro-2-formyl-3-hydroxyphenoxy)pentanoic acid;  
 5-(3-acetylamino-2-formyl phenoxy)pentanoic acid;  
 Aminoguanidine;  
 4-(2-formyl-3-hydroxyphenoxy)butanoic acid;  
 6-(2-formyl-3-hydroxyphenoxy)hexanoic acid;  
 ethyl 4-(3-acetylamino-2-formylphenoxy)methylbenzoate;  
 4-(3-acetylamino-2-formylphenoxy)methylbenzoic acid;  
 2-(2-formyl-3-hydroxyphenoxy)methylbenzoic acid;  
 5-[4-(2-formyl-3-hydroxyphenoxy)methyl]phenyl]tetrazole;  
 5-(2-formyl-3-hydroxy-4-methoxyphenoxy)pentanoic acid;  
 3-(2-formyl-3-hydroxyphenoxy)propionitrile;  
 4-Hydroxyphenylacetaldehyde;  
 Phenylacetaldehyde;  
 4-Methoxyphenylacetaldehyde;  
 1-hydroxy-2-phenylpropane;  
 3-Phenylpropanaldehyde;  
 4-Nitrobenzaldehyde;  
 Methyl 4-formylbenzoate;

12  
 CONT

C3  
CONT

4-Chlorobenzaldehyde;  
4-Methoxybenzaldehyde;  
4-Methylbenzaldehyde;  
8,10-Dioxoundecanoic acid;  
4,6-Dioxoheptanoic acid;  
Pentanedione;  
5-methoxy-1-tetralone;  
6-methoxy-1-tetralone;  
7-methoxy-1-tetralone;  
2-tetralone;  
3-hydroxy-1-(4-methoxyphenyl)-3-methyl-2-butanone;  
2',4'-dihydroxy-2-(4-methoxyphenyl)acetophenone;  
2-hydroxy-1-(4-methoxyphenyl)-pent-2-ene-4-one;  
Naringenin 4',5,6-trihydroxyflavonone;  
4'-methoxy-2-(4-methoxyphenyl)acetophenone;  
6,7-dihydroxycoumarin;  
7-methoxy-2-tetralone;  
6,7-dimethoxy-2-tetralone;  
6-hydroxy-4-methylcoumarin;  
Homogentisic acid gamma lactone;  
6-hydroxy-1,2-naphthoquinone;  
8-methoxy-2-tetralone;

and physiologically acceptable salts thereof, where appropriate.

C3

24. (Amended) A combination of components for separate, sequential or concomitant administration in a method of vaccinating a mammal against a disease state, comprising administering to said mammal, within an appropriate vector, a nucleotide sequence encoding an antigenic peptide associated with the disease state; additionally administering to said mammal a Schiff base forming compound which enhances both humoral and cellular immune responses initiated by the antigenic peptide, the compound being selected from the group consisting of:

4-(2-formyl-3-hydroxyphenoxy)methyl)benzoic acid;  
5-(2-formyl-3-hydroxyphenoxy)pentanamide;  
*N,N*-diethyl 5-(2-formyl-3-hydroxyphenoxy)pentanamide;  
*N*-isopropyl 5-(2-formyl-3-hydroxyphenoxy)pentanamide;  
ethyl 5-(2-formyl-3-hydroxyphenoxy)pentanoate;  
5-(2-formyl-3-hydroxyphenoxy)pentanonitrile;  
(±)-5-(2-formyl-3-hydroxyphenoxy)-2-methylpentanoic acid;  
5-(2-formyl-3-hydroxyphenoxy)-2,2-dimethylpentanoic acid;  
methyl 3-(2-formyl-3-hydroxyphenoxy)methylbenzoate;  
3-(2-formyl-3-hydroxyphenoxy)methylbenzoic acid;  
benzyl 5-(2-formyl-3-hydroxyphenoxy)pentanoate;  
5-[4-(2-formyl-3-hydroxyphenoxy)-*N*-butyl]tetrazole;  
7-(2-formyl-3-hydroxyphenoxy)heptanoic acid;  
5-(2-formyl-3-hydroxy-4-*n*-propoxyphenoxy)pentanoic acid;  
5-(4,6-dichloro-2-formyl-3-hydroxyphenoxy)pentanoic acid;  
5-(2-formyl-3-hydroxyphenoxy)-*N*-methylsulphonylpentanamide;  
ethyl 4-(2-formyl-3-hydroxyphenoxy)methyl)benzoate;  
5-(4-chloro-2-formyl-3-hydroxyphenoxy)pentanoic acid;  
5-(3-acetylamino-2-formyl phenoxy)pentanoic acid;  
Aminoguanidine;  
4-(2-formyl-3-hydroxyphenoxy)butanoic acid;  
6-(2-formyl-3-hydroxyphenoxy)hexanoic acid;  
ethyl 4-(3-acetylamino-2-formylphenoxy)methyl)benzoate;  
4-(3-acetylamino-2-formylphenoxy)methyl)benzoic acid;  
2-(2-formyl-3-hydroxyphenoxy)methyl)benzoic acid;  
5-[4-(2-formyl-3-hydroxyphenoxy)methyl)phenyl]tetrazole;  
5-(2-formyl-3-hydroxy-4-methoxyphenoxy)pentanoic acid;  
3-(2-formyl-3-hydroxyphenoxy)propionitrile;  
4-Hydroxyphenylacetaldehyde;  
Phenylacetaldehyde;  
4-Methoxyphenylacetaldehyde;

13  
cont

1-hydroxy-2-phenylpropane;  
3-Phenylpropanaldehyde;  
4-Nitrobenzaldehyde;  
Methyl 4-formylbenzoate;  
4-Chlorobenzaldehyde;  
4-Methoxybenzaldehyde;  
4-Methylbenzaldehyde;  
8,10-Dioxoundecanoic acid;  
4,6-Dioxoheptanoic acid;  
Pentanedione;  
5-methoxy-1-tetralone;  
6-methoxy-1-tetralone;  
7-methoxy-1-tetralone;  
2-tetralone;  
3-hydroxy-1-(4-methoxyphenyl)-3-methyl-2-butanone;  
2',4'-dihydroxy-2-(4-methoxyphenyl)acetophenone;  
2-hydroxy-1-(4-methoxyphenyl)-pent-2-ene-4-one;  
Naringenin 4',5,6-trihydroxyflavonone;  
4'-methoxy-2-(4-methoxyphenyl)acetophenone;  
6,7-dihydroxycoumarin;  
7-methoxy-2-tetralone;  
6,7-dimethoxy-2-tetralone;  
6-hydroxy-4-methylcoumarin;  
Homogentisic acid gamma lactone;  
6-hydroxy-1,2-naphthoquinone;  
8-methoxy-2-tetralone;

and physiologically acceptable salts thereof, where appropriate;  
wherein the combination comprises the nucleotide sequence encoding for an antigenic peptide and the compound which enhances both humoral and cellular immune responses initiated by the antigenic peptide.